Pemafibrate - Kowa Pharmaceutical

Drug Profile

Pemafibrate - Kowa Pharmaceutical

Alternative Names: K 877; Parmodia

Latest Information Update: 16 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kowa Pharmaceutical
  • Developer Jaeb Center for Health Research; Kowa Pharmaceutical
  • Class Antihyperlipidaemics; Benzoxazoles; Butyric acids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Hyperlipidaemia
  • Phase III Diabetic retinopathy; Dyslipidaemias; Hypertriglyceridaemia
  • Phase II Non-alcoholic fatty liver disease
  • Phase I Primary biliary cirrhosis

Most Recent Events

  • 15 Jan 2018 Phase-III clinical trials in Diabetic retinopathy (Prevention) in USA (PO) (NCT03345901)
  • 27 Dec 2017 Phase-II clinical trials in Non-alcoholic fatty liver disease in Japan (PO) (NCT03350165)
  • 22 Nov 2017 Kowa Pharmaceutical plans a phase II trial in Non-alcoholic fatty liver disease in Japan (NCT03350165)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top